Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 5/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518754 | 0.93 | TSHR (0.62) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL3901758 | 0.90 | TSHR (0.65) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL5360732 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL27985636 | 0.85 | TSHR (0.60) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL6766743 | 0.85 | TSHR (0.54) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL26479936 | 0.83 | TSHR (0.71) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL27799665 | 0.83 | TSHR (1.00) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| SCHEMBL15072 | 0.83 | — | — | |
| SCHEMBL5693386 | 0.82 | TSHR (0.56) | TSHRALDH1A1MAPK1TDP1CYP2C19 | |
| Water SCHEMBL23706522 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097070-A1 | ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| CN-117020933-A | White pad for semiconductor polishing and production process thereof | 安徽禾臣新材料有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-117025115-A | Preparation method of adsorption pad for mask plate processing | 安徽禾臣新材料有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-117020978-A | Preparation method of buffering damping cloth for optical lens processing | 安徽禾臣新材料有限公司 | 2023-11-10 | — | — | CN | claimed |
| US-20200239680-A1 | INTERPENETRATING POLYMER NETWORK CONTAINING CROSS-LINKED POLY(N-VINYLAMINE) | KEMIRA OYJ (FI) | 2020-07-30 | — | — | US | claimed |
| US-10584217-B2 | Method for producing a material with a network of at least two polymers, a product thereof and use of the product | KEMIRA OYJ (FI) | 2020-03-10 | — | — | US | claimed |
| US-10577471-B2 | Method for curing curable compositions | BASF SE (DE) | 2020-03-03 | — | — | US | claimed |
| US-10189935-B2 | Water soluble cross-linked block copolymers | KEMIRA OYJ (FI) | 2019-01-29 | — | — | US | claimed |
| US-10174134-B2 | Polymer product, method for producing the polymer and use of the polymer | KEMIRA OYJ (FI) | 2019-01-08 | — | — | US | claimed |
| EP-3201261-B1 | METHOD FOR CURING CURABLE COMPOSITIONS | BASF SE (DE) | 2018-12-12 | — | — | EP | claimed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | claimed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| EP-0716606-B1 | PHOSPHATE-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX PHARMA INC (US) | 2001-08-29 | — | — | EP | claimed |
| US-6264937-B1 | MIXTURE WITH LIPASE INHIBITOR | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | claimed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | claimed |
| EP-1043981-A2 | FAT-BINDING POLYMERS COMBINED WITH LIPASE INHIBITORS | Geltex Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5925379-A | REMOVING BILE SALTS FROM PATIENT BY ADMINISTERING INTERPENETRATING POLYMER NETWORK COMPRISING CATIONIC POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1999034787-A2 | FAT-BINDING POLYMERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | claimed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | claimed |
| US-4844889-A | FOR HAIR AND SKIN, PROTECTION AGAINST PHOTODEGRADATION | L'OREAL (FR) | 1989-07-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | TSHR 622/4885ALDH1A1 4693/4885MAPK1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.